

## **Supplementary Appendix**



**Supplementary Figure 1. Flow chart of study eligibility.** Frequencies are rounded to the nearest 5. CKD, chronic kidney disease; eGFR, estimated glomerular filtrate rate; RRT, renal replacement therapy.



Supplementary Figure 2. Factors associated with completion of a 4-dose vaccine series in kidney disease subgroups. Individuals were included in the analysis if they were ≥75 years of age at baseline, care home residents, transplant recipients, or had a history of haematologic malignancy or immunosuppression. Hazard ratios and 95% confidence intervals were derived from partially adjusted models that included age, care home residence, health and social care worker status, housebound status, receipt of end-of-life care, setting (urban/rural), sex, ethnicity, IMD quintile, prior SARS-CoV-2 infection, immunosuppression, and haematologic cancer. Data are redacted [R] for any rows in which there were >0 and ≤10 event or non-event counts after rounding to the nearest 5, with non-event counts calculated among uncensored individuals. CKD, chronic kidney disease; IMD, index of multiple deprivation; [N], covariate absent in all individuals by definition; [R], redacted; RRT, renal replacement therapy.

Supplementary Table 1. Product profile by dose.

supprementary ruble is frome by usses												
Subgroup	Dose 1	Dose 2	Dose 3	Dose 4								
Product												
BNT	483,280 (53.5%)	473,820 (53.8%)	742,985 (92.1%)	178,065 (47.0%)								
AZ	418,795 (46.4%)	405,975 (46.1%)	1,910 (0.2%)	110 (0.0%)								
MOD	570 (0.1%)	905 (0.1%)	61,515 (7.6%)	200,445 (52.9%)								
2-dose product combination												
BNT-BNT	_	470,655 (53.4%)	_	_								
AZ-AZ	_	402,395 (45.7%)	_	_								
BNT-AZ	_	3,580 (0.4%)	_	_								
AZ-BNT	_	3,125 (0.4%)	_	_								
Other	_	945 (0.1%)	_	_								
3-dose product combination												
BNT-BNT-BNT	_	_	419,020 (52.0%)	_								
AZ-AZ-BNT	_	_	320,100 (39.7%)	_								
AZ-AZ-MOD	_	_	40,875 (5.1%)	_								
BNT-BNT-MOD	_	_	20,015 (2.5%)	_								
BNT-AZ-BNT	_	_	2,490 (0.3%)	_								
AZ-AZ-AZ	_	_	1,670 (0.2%)	_								
AZ-BNT-BNT	_	_	1,185 (0.1%)	_								
Other	_	_	1,060 (0.1%)	_								

Frequencies are rounded to the nearest 5. Any dose combinations given to <1000 individuals were pooled as 'Other'. AZ, ChAdOx1-S (AstraZeneca); BNT, BNT162b2 (Pfizer-BioNTech); MOD, mRNA-1273 (Moderna).

Supplementary Table 2. Cox proportional hazards model and logistic regression outputs for factors associated with completion of a 3-dose vaccination series in people with kidney disease.

		Logistic r	Logistic regression				
Variable	N (n events)	Cov. (%)	HR (95% CI), minimally adjusted	HR (95% CI), partially adjusted	HR (95% CI), fully adjusted	N (n events)	OR (95% CI), partially adjusted
*†Age	104 550 (04 015)	0.4.1	1.00	1.00	1.00	00.200 (02.700)	1.00
16–64 (ref)	104,770 (84,815)	84.1	1.00	1.00	1.00	99,200 (83,700)	1.00
65–69	70,790 (62,075)	91.6	1.32 (1.31–1.33)	1.29 (1.27–1.30)	1.31 (1.30–1.33)	66,485 (61,115)	1.90 (1.83–1.96)
70–74	135,900 (122,380)	94.5	1.75 (1.73–1.77)	1.67 (1.66–1.69)	1.71 (1.70–1.73)	126,665 (120,080)	2.69 (2.61–2.78)
75–79	172,530 (155,085)	95.5	2.18 (2.16–2.20)	2.09 (2.07–2.11)	2.15 (2.13–2.17)	157,535 (150,935)	3.30 (3.20–3.40)
80+	464,860 (381,885)	95.0	2.45 (2.43–2.47)	2.46 (2.44–2.48)	2.55 (2.53–2.57)	371,785 (355,415)	3.20 (3.12–3.28)
†Sex							
Female (ref)	530,685 (451,975)	93.2	1.00	1.00	1.00	462,955 (433,405)	1.00
Male	418,160 (354,265)	93.8	1.11 (1.11–1.12)	1.10 (1.09–1.10)	1.10 (1.10–1.11)	358,715 (337,840)	1.18 (1.16–1.20)
†Ethnicity							
White (ref)	888,875 (764,800)	94.7	1.00	1.00	1.00	768,730 (731,110)	1.00
Mixed	5,110 (3,670)	77.1	0.61 (0.59–0.63)	0.63 (0.61–0.65)	0.63 (0.61–0.65)	4,590 (3,560)	0.30 (0.28-0.32)
Asian or Asian British	32,245 (23,100)	78.6	0.62 (0.61–0.63)	0.66 (0.65–0.67)	0.66 (0.65–0.67)	28,185 (22,340)	0.33 (0.32-0.35)
Black or Black British	16,345 (10,035)	65.8	0.46 (0.45-0.47)	0.48 (0.47-0.49)	0.48 (0.47-0.49)	14,725 (9,780)	0.20 (0.20-0.21)
Other ethnic groups	6,270 (4,640)	81.3	0.68 (0.66-0.70)	0.69 (0.67-0.71)	0.69 (0.67-0.71)	5,440 (4,455)	0.34 (0.31-0.36)
†IMD							
1 most deprived (ref)	158,960 (125,290)	87.6	1.00	1.00	1.00	135,750 (119,600)	1.00
2	180,015 (149,635)	92.0	1.18 (1.17–1.19)	1.14 (1.14–1.15)	1.14 (1.13–1.15)	154,825 (143,160)	1.44 (1.40–1.48)
3	214,280 (184,140)	94.4	1.31 (1.30–1.32)	1.25 (1.24–1.26)	1.24 (1.23–1.25)	185,775 (176,125)	1.83 (1.78–1.88)
4	207,080 (180,565)	95.5	1.40 (1.39–1.41)	1.32 (1.31–1.33)	1.31 (1.30–1.32)	180,325 (172,735)	2.10 (2.03–2.16)
5 least deprived	188,510 (166,605)	96.4	1.52 (1.51–1.53)	1.43 (1.42–1.44)	1.42 (1.41–1.43)	164,995 (159,625)	2.60 (2.52–2.69)
†Setting	, , , ,			,		, , , ,	,
Urban city or town (ref)	506,660 (432,255)	93.8	1.00	1.00	1.00	439,015 (413,745)	1
Urban conurbation	199,215 (160,590)	89.3	0.95 (0.94-0.96)	1.01 (1.01–1.02)	1.01 (1.00–1.02)	170,700 (153,335)	0.87 (0.85-0.90)
Rural town or village	242,975 (213,390)	96.0	1.08 (1.08–1.09)	1.01 (1.01–1.02)	1.01 (1.01–1.02)	211,955 (204,170)	1.20 (1.16–1.23)
Kidney disease subgroup	, ( -,,		( ,		- ( /	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	- ( /
CKD3a (ref)	627,265 (547,740)	93.7	1.00	1.00	1.00	563,295 (529,545)	1.00
CKD3b	236,205 (194,455)	93.8	0.92 (0.92–0.93)	0.94 (0.93-0.94)	0.93 (0.92–0.93)	193,880 (182,825)	0.94 (0.92–0.96)
CKD4-5	63,165 (46,400)	91.7	0.84 (0.83–0.85)	0.87 (0.87–0.88)	0.86 (0.85–0.87)	45,450 (42,055)	0.84 (0.81–0.88)
RRT (dialysis)	9,440 (6,880)	86.3	1.03 (1.00–1.05)	1.09 (1.07–1.12)	1.07 (1.05–1.10)	7,280 (6,335)	1.06 (0.99–1.15)
RRT (transplant)	12,770 (10,765)	88.7	1.54 (1.51–1.57)	1.45 (1.42–1.49)	1.44 (1.41–1.47)	11,765 (10,490)	1.09 (1.01–1.17)
Primary care coding of kidney disease	1=,,,, (10,, 00)	00.7	1.01 (1.01 1.07)	1.10 (1.12 1.17)	1.11 (1.11 1.17)	11,700 (10,170)	1.07 (1.01 1.17)
CKD diagnostic code	563,335 (478,860)	94.1	1.03 (1.02–1.03)	1.04 (1.03–1.04)	1.06 (1.06–1.07)	482,525 (456,065)	1.23 (1.21–1.25)
Risk group (occupation/access)	(170,000)	/ 1.1	1.00 (1.02 1.00)	1.01 (1.00 1.04)	1.00 (1.00 1.07)	102,020 (100,000)	1.20 (1.21 1.20)
*†Care home resident	43,385 (27,150)	94.5	1.01 (1.00–1.02)	1.06 (1.05–1.07)	1.11 (1.10–1.12)	23,070 (21,910)	1.02 (0.96–1.09)
*tHealth/social care worker	5,175 (4,770)	93.2	2.15 (2.09–2.21)	2.27 (2.21–2.34)	2.25 (2.19–2.32)	5,060 (4,730)	2.66 (2.36–2.99)
†Housebound	53,520 (37,175)	92.4	0.60 (0.59–0.60)	0.61 (0.61–0.62)	0.63 (0.62–0.63)	35,160 (32,795)	0.79 (0.76–0.83)
11 IOUSEDOUIIU	55,540 (57,175)	24.4	0.00 (0.35-0.00)	0.01 (0.01-0.02)	0.03 (0.02-0.03)	00,100 (04,790)	0.7 5 (0.7 0-0.00)

39,430 (23,495)	92.6	0.82 (0.81-0.83)	0.87 (0.85-0.88)	0.87 (0.86-0.88)	21,080 (19,740)	0.86 (0.81-0.91)
25,490 (17,785)	90.7	0.89 (0.88-0.91)	0.94 (0.92-0.95)	0.94 (0.93-0.96)	17,785 (16,230)	0.96 (0.91-1.02)
80,025 (67,140)	93.8	1.17 (1.16–1.18)	1.19 (1.18-1.20)	1.11 (1.10–1.12)	67,605 (63,680)	1.39 (1.34–1.45)
108,950 (94,075)	92.5	0.93 (0.92-0.94)	0.97 (0.96–0.97)	0.98 (0.97–0.99)	98,525 (91,440)	1.11 (1.08–1.14)
269,895 (222,880)	92.6	0.91 (0.90-0.91)	0.95 (0.95-0.96)	0.96 (0.96–0.97)	227,180 (211,585)	1.06 (1.04–1.08)
210,095 (174,610)	93.5	0.98 (0.98-0.99)	1.01 (1.00-1.01)	1.01 (1.01–1.02)	176,195 (165,520)	1.05 (1.03–1.08)
425,575 (352,775)	94.4	0.98 (0.98-0.99)	0.98 (0.97-0.98)	0.99 (0.98-0.99)	349,835 (331,995)	1.06 (1.04–1.09)
31,285 (26,060)	91.9	1.00 (0.99–1.01)	1.01 (0.99–1.02)	1.01 (1.00–1.02)	27,045 (24,990)	1.01 (0.96–1.06)
8,405 (7,180)	94.3	1.10 (1.07-1.12)	1.08 (1.06-1.11)	1.08 (1.06–1.11)	7,270 (6,875)	1.19 (1.07-1.32)
164,110 (136,440)	95.4	1.09 (1.08-1.10)	1.07 (1.06–1.08)	1.07 (1.06–1.08)	134,180 (128,730)	1.30 (1.27-1.34)
19,990 (16,325)	95.4	1.16 (1.14–1.18)	0.99 (0.97-1.00)	1.04 (1.03–1.06)	15,800 (15,175)	1.07 (0.98–1.18)
2,170 (1,865)	93.0	1.46 (1.39–1.52)	1.31 (1.26–1.38)	1.39 (1.33–1.46)	1,910 (1,795)	1.41 (1.16–1.72)
158,200 (124,130)	93.4	0.89 (0.88–0.89)	0.90 (0.90-0.91)	0.91 (0.90-0.91)	121,505 (114,275)	0.90 (0.87-0.92)
16,270 (12,665)	87.2	0.76 (0.75–0.77)	0.79 (0.78-0.81)	0.80 (0.78-0.81)	13,735 (12,055)	0.67 (0.63-0.70)
5,750 (4,815)	91.6	1.01 (0.98–1.03)	1.05 (1.02–1.08)	1.03 (1.00–1.06)	4,965 (4,580)	0.93 (0.83–1.04)
	25,490 (17,785) 80,025 (67,140) 108,950 (94,075) 269,895 (222,880) 210,095 (174,610) 425,575 (352,775) 31,285 (26,060) 8,405 (7,180) 164,110 (136,440) 19,990 (16,325) 2,170 (1,865) 158,200 (124,130) 16,270 (12,665)	25,490 (17,785) 90.7 80,025 (67,140) 93.8 108,950 (94,075) 92.5 269,895 (222,880) 92.6 210,095 (174,610) 93.5 425,575 (352,775) 94.4 31,285 (26,060) 91.9 8,405 (7,180) 94.3 164,110 (136,440) 95.4 19,990 (16,325) 95.4 2,170 (1,865) 93.0 158,200 (124,130) 93.4 16,270 (12,665) 87.2	25,490 (17,785) 90.7 0.89 (0.88–0.91) 80,025 (67,140) 93.8 1.17 (1.16–1.18) 108,950 (94,075) 92.5 0.93 (0.92–0.94) 269,895 (222,880) 92.6 0.91 (0.90–0.91) 210,095 (174,610) 93.5 0.98 (0.98–0.99) 425,575 (352,775) 94.4 0.98 (0.98–0.99) 31,285 (26,060) 91.9 1.00 (0.99–1.01) 8,405 (7,180) 94.3 1.10 (1.07–1.12) 164,110 (136,440) 95.4 1.09 (1.08–1.10) 19,990 (16,325) 95.4 1.16 (1.14–1.18) 2,170 (1,865) 93.0 1.46 (1.39–1.52) 158,200 (124,130) 93.4 0.89 (0.88–0.89) 16,270 (12,665) 87.2 0.76 (0.75–0.77)	25,490 (17,785) 90.7 0.89 (0.88–0.91) 0.94 (0.92–0.95) 80,025 (67,140) 93.8 1.17 (1.16–1.18) 1.19 (1.18–1.20) 108,950 (94,075) 92.5 0.93 (0.92–0.94) 0.97 (0.96–0.97) 269,895 (222,880) 92.6 0.91 (0.90–0.91) 0.95 (0.95–0.96) 210,095 (174,610) 93.5 0.98 (0.98–0.99) 1.01 (1.00–1.01) 425,575 (352,775) 94.4 0.98 (0.98–0.99) 0.98 (0.97–0.98) 31,285 (26,060) 91.9 1.00 (0.99–1.01) 1.01 (0.99–1.02) 8,405 (7,180) 94.3 1.10 (1.07–1.12) 1.08 (1.06–1.11) 164,110 (136,440) 95.4 1.09 (1.08–1.10) 1.07 (1.06–1.08) 19,990 (16,325) 95.4 1.16 (1.14–1.18) 0.99 (0.97–1.00) 2,170 (1,865) 93.0 1.46 (1.39–1.52) 1.31 (1.26–1.38) 158,200 (124,130) 93.4 0.89 (0.88–0.89) 0.90 (0.90–0.91) 16,270 (12,665) 87.2 0.76 (0.75–0.77) 0.79 (0.78–0.81)	25,490 (17,785) 90.7 0.89 (0.88-0.91) 0.94 (0.92-0.95) 0.94 (0.93-0.96) 80,025 (67,140) 93.8 1.17 (1.16-1.18) 1.19 (1.18-1.20) 1.11 (1.10-1.12) 108,950 (94,075) 92.5 0.93 (0.92-0.94) 0.97 (0.96-0.97) 0.98 (0.97-0.99) 269,895 (222,880) 92.6 0.91 (0.90-0.91) 0.95 (0.95-0.96) 0.96 (0.96-0.97) 210,095 (174,610) 93.5 0.98 (0.98-0.99) 1.01 (1.00-1.01) 1.01 (1.01-1.02) 425,575 (352,775) 94.4 0.98 (0.98-0.99) 0.98 (0.97-0.98) 0.99 (0.98-0.99) 31,285 (26,060) 91.9 1.00 (0.99-1.01) 1.01 (0.99-1.02) 1.01 (1.00-1.02) 8,405 (7,180) 94.3 1.10 (1.07-1.12) 1.08 (1.06-1.11) 1.08 (1.06-1.11) 164,110 (136,440) 95.4 1.09 (1.08-1.10) 1.07 (1.06-1.08) 1.07 (1.06-1.08) 19,990 (16,325) 95.4 1.16 (1.14-1.18) 0.99 (0.97-1.00) 1.04 (1.03-1.06) 2,170 (1,865) 93.0 1.46 (1.39-1.52) 1.31 (1.26-1.38) 1.39 (1.33-1.46) 158,200 (124,130) 93.4 0.89 (0.88-0.89) 0.90 (0.90-0.91) 0.91 (0.90-0.91) 16,270 (12,665) 87.2 0.76 (0.75-0.77) 0.79 (0.78-0.81) 0.80 (0.78-0.81)	25,490 (17,785) 90.7 0.89 (0.88-0.91) 0.94 (0.92-0.95) 0.94 (0.93-0.96) 17,785 (16,230) 80,025 (67,140) 93.8 1.17 (1.16-1.18) 1.19 (1.18-1.20) 1.11 (1.10-1.12) 67,605 (63,680) 108,950 (94,075) 92.5 0.93 (0.92-0.94) 0.97 (0.96-0.97) 0.98 (0.97-0.99) 98,525 (91,440) 269,895 (222,880) 92.6 0.91 (0.90-0.91) 0.95 (0.95-0.96) 0.96 (0.96-0.97) 227,180 (211,585) 210,095 (174,610) 93.5 0.98 (0.98-0.99) 1.01 (1.00-1.01) 1.01 (1.01-1.02) 176,195 (165,520) 425,575 (352,775) 94.4 0.98 (0.98-0.99) 0.98 (0.97-0.98) 0.99 (0.98-0.99) 349,835 (331,995) 31,285 (26,060) 91.9 1.00 (0.99-1.01) 1.01 (0.99-1.02) 1.01 (1.00-1.02) 27,045 (24,990) 8,405 (7,180) 94.3 1.10 (1.07-1.12) 1.08 (1.06-1.11) 1.08 (1.06-1.11) 7,270 (6,875) 164,110 (136,440) 95.4 1.09 (1.08-1.10) 1.07 (1.06-1.08) 1.07 (1.06-1.08) 134,180 (128,730) 19,990 (16,325) 95.4 1.16 (1.14-1.18) 0.99 (0.97-1.00) 1.04 (1.03-1.06) 15,800 (15,175) 2,170 (1,865) 93.0 1.46 (1.39-1.52) 1.31 (1.26-1.38) 1.39 (1.33-1.46) 1,910 (1,795) 158,200 (124,130) 93.4 0.89 (0.88-0.89) 0.90 (0.90-0.91) 0.91 (0.90-0.91) 121,505 (114,275) 16,270 (12,665) 87.2 0.76 (0.75-0.77) 0.79 (0.78-0.81) 0.80 (0.78-0.81) 13,735 (12,055)

Cumulative coverage was determined based on Kaplan-Meier estimates, censoring on death, deregistration, or 11<sup>th</sup> May 2022. Logistic regression models included 821,670 individuals who were uncensored (registered and alive) as of the analysis cut-off (11<sup>th</sup> May 2022). \* variable included in all minimally adjusted models; † variable included in all partially adjusted models. CI, confidence interval; CKD, chronic kidney disease; HR, hazard ratio; IMD, index of multiple deprivation; OR, odds ratio; RRT, renal replacement therapy.

Supplementary Table 3. Cox proportional hazards models for factors associated with completion of a 3-dose vaccination series in kidney disease subgroups.

	1	CKD3a CKD3b				CKD4-5			RRT (dialy			RT (transp	ant)		
		Cov.			Cov.			Cov.			Cov.			Cov.	
Variable	N (n events)	(%)	HR (95% CI)	N (n events)	(%)	HR (95% CI)	N (n events)	(%)	HR (95% CI)	N (n events)	(%)	HR (95% CI)	N (n events)	(%)	HR (95% CI)
*†Age															
16-64 (ref)	71,970 (59,135)	84.5	1.00	13,245 (10,360)	82.5	1.00	5,870 (4,385)	80.7	1.00	4,390 (3,165)	79.9	1.00	9,295 (7,770)	86.7	1.00
65–69	54,435 (48,425)	92.0	1.34 (1.32–1.36)	10,815 (9,205)	90.5	1.28 (1.25–1.32)	3,020 (2,355)	88.1	1.25 (1.19–1.32)	1,095 (830)	88.0	1.26 (1.17–1.37)	1,425 (1,260)	94.3	1.38 (1.30–1.47)
70–74	102,975 (94,125)	94.8	1.80 (1.78-1.82)	24,730 (21,670)	93.8	1.62 (1.58-1.65)	5,865 (4,700)	91.2	1.45 (1.39–1.51)	1,145 (855)	90.3	1.35 (1.25-1.46)	1,180 (1,035)	94.2	1.40 (1.31-1.50)
75–79	124,030 (113,350)	95.7	2.27 (2.25-2.29)	38,245 (33,655)	95.0	2.00 (1.96-2.05)	8,410 (6,645)	93.5	1.80 (1.73-1.87)	1,220 (920)	94.5	1.64 (1.52-1.77)	620 (510)	94.0	1.47 (1.34-1.61)
80+	273,855 (232,705)	95.3	2.71 (2.69-2.74)	149,170 (119,565)	94.8	2.36 (2.31-2.41)	40,000 (28,315)	93.5	2.07 (2.00-2.14)	1,590 (1,110)	93.1	1.91 (1.78-2.05)	[R}	[R}	[R]
†Sex															
Female (ref)	355,460 (310,735)	93.4	1.00	134,120 (110,490)	93.4	1.00	32,700 (24,050)	91.3	1.00	3,480 (2,530)	84.7	1.00	4,925 (4,175)	88.5	1.00
Male	271,805 (237,005)	94.0	1.09 (1.08-1.09)	102,085 (83,965)	94.2	1.12 (1.11-1.14)	30,465 (22,355)	92.1	1.13 (1.11-1.15)	5,960 (4,355)	87.0	1.04 (0.99-1.09)	7,845 (6,590)	88.6	0.98 (0.95-1.02)
†Ethnicity															
White (ref)	590,315 (521,735)	94.9	1.00	222,900 (185,385)	94.9	1.00	57,975 (43,250)	93.5	1.00	7,295 (5,415)	88.9	1.00	10,390 (9,015)	91.2	1.00
Mixed	3,415 (2,470)	76.1	0.61 (0.59-0.64)	1,065 (770)	79.8	0.66 (0.61-0.70)	350 (220)	73.6	0.60 (0.52-0.68)	140 (105)	76.9	0.89 (0.73-1.08)	140 (100)	71.4	0.65 (0.54-0.80)
Asian or Asian British	18,720 (13,805)	79.0	0.64 (0.63-0.65)	7,595 (5,310)	78.3	0.65 (0.64-0.67)	3,120 (1,915)	74.7	0.65 (0.62-0.68)	1,295 (920)	80.6	0.85 (0.78-0.91)	1,510 (1,145)	79.4	0.72 (0.67-0.77)
Black or Black British	10,840 (6,710)	65.1	0.48 (0.46-0.49)	3,240 (1,965)	66.8	0.47 (0.45-0.50)	1,225 (695)	65.5	0.49 (0.45-0.53)	570 (355)	67.5	0.60 (0.54-0.68)	470 (310)	68.9	0.54 (0.48-0.60)
Other ethnic groups	3,975 (3,015)	81.6	0.68 (0.65-0.70)	1,405 (1,025)	82.0	0.71 (0.67-0.76)	495 (320)	76.1	0.70 (0.63-0.78)	135 (85)	66.2	0.67 (0.54-0.83)	260 (190)	76.7	0.71 (0.61-0.82)
†IMD															
1 most deprived (ref)	100,965 (82,025)	87.9	1.00	40,770 (31,390)	88.5	1.00	12,015 (8,120)	84.9	1.00	2,610 (1,770)	78.8	1.00	2,600 (1,990)	80.2	1.00
2	116,850 (99,945)	92.2	1.15 (1.14–1.16)	45,630 (36,860)	92.5	1.12 (1.11–1.14)	12,685 (9,090)	90.2	1.16 (1.12–1.19)	2,185 (1,555)	84.8	1.21 (1.13–1.30)	2,665 (2,185)	86.0	1.22 (1.15-1.30)
3	141,655 (124,995)	94.6	1.24 (1.23–1.26)	53,770 (44,755)	94.8	1.23 (1.21–1.25)	14,205 (10,595)	92.9	1.26 (1.22–1.30)	1,890 (1,425)	88.2	1.31 (1.21–1.41)	2,760 (2,370)	90.2	1.38 (1.30–1.47)
4	139,220 (124,375)	95,6	1.32 (1.31–1.33)	50,790 (42,810)	95.6	1.30 (1.28–1.32)	13,015 (9,975)	94.5	1.33 (1.29–1.37)	1,530 (1,195)	91.2	1.41 (1.30–1.52)	2,520 (2,210)	92.2	1.52 (1.43–1.62)
5 least deprived	128,575 (116,400)	96.6	1.44 (1.42–1.45)	45,240 (38,635)	96.4	1.40 (1.37–1.42)	11,245 (8,625)	95.4	1.43 (1.38–1.48)	1,230 (935)	91.6	1.46 (1.34–1.59)	2,225 (2,010)	93.8	1.62 (1.51–1.73)
	120,575 (110,400)	70.0	1.44 (1.42-1.43)	45,240 (56,655)	70.1	1.40 (1.57-1.42)	11,245 (0,025)	75.4	1.45 (1.50-1.40)	1,230 (333)	71.0	1.40 (1.54-1.57)	2,223 (2,010)	75.0	1.02 (1.51–1.75)
†Setting Urban city or town (ref)	334,925 (293,565)	94.0	1.00	126 760 (104 920)	94.2	1.00	33,625 (24,845)	92.4	1.00	4,735 (3,400)	86.0	1.00	6,615 (5,630)	89.3	1.00
Urban conurbation	128,630 (106,790)	89.7	1.01 (1.00–1.02)	126,760 (104,820) 49,545 (38,800)	89.8	1.02 (1.00–1.03)	14,540 (10,095)	86.3	1.00 (0.97–1.03)	3,000 (2,135)	82.4	1.12 (1.03–1.21)	3,495 (2,770)	83.1	1.06 (1.00–1.13)
Rural town or village	163,705 (147,385)	96.1	1.01 (1.00–1.02)	59,900 (50,830)	96.1	1.01 (1.00–1.02)	15,000 (11,460)	95.2	1.03 (1.01–1.05)	1,705 (1,345)	93.2	1.12 (1.05–1.21)	2,660 (2,370)	93.5	1.05 (1.00–1.13)
	165,705 (147,385)	96.1	1.01 (1.00-1.02)	59,900 (50,830)	96.1	1.01 (1.00-1.02)	15,000 (11,460)	95.2	1.03 (1.01-1.05)	1,705 (1,345)	93.2	1.18 (1.10-1.26)	2,000 (2,370)	93.5	1.05 (1.00-1.10)
Primary care coding of kidney disease				/									. (== ()		
CKD diagnostic code	306,820 (270,530)	94.5	1.05 (1.04-1.05)	183,225 (152,815)	94.3	1.08 (1.07–1.09)	55,645 (41,425)	92.2	1.17 (1.13–1.20)	7,990 (5,895)	87.6	1.14 (1.07-1.22)	9,655 (8,200)	89.6	1.10 (1.05-1.15)
Risk group (occupation/access)															
*†Care home resident	23,700 (15,635)	94.5	1.03 (1.02-1.05)	14,845 (8,955)	94.6	1.09 (1.06-1.11)	4,605 (2,425)	93.2	1.14 (1.09–1.19)	[R]	[R]	[R]	[R]	[R]	[R]
*†Health/social care worker	3,975 (3,680)	93.5	2.35 (2.27-2.43)	585 (530)	89.7	2.03 (1.87-2.22)	195 (170)	84.2	2.08 (1.79-2.42)	[R]	[R]	[R]	355 (335)	91.7	2.09 (1.87-2.33)
†Housebound	26,735 (19,485)	92.7	0.60 (0.59-0.61)	18,770 (12,815)	92.4	0.63 (0.62-0.64)	6,800 (3,985)	90.4	0.65 (0.63-0.67)	600 (370)	88.4	0.91 (0.82-1.01)	615 (520)	89.2	0.92 (0.84-1.00)
†End of life care	20,070 (12,665)	92.9	0.86 (0.85-0.88)	13,185 (7,700)	92.9	0.89 (0.87-0.91)	5,385 (2,640)	90.7	0.88 (0.85-0.92)	600 (355)	84.7	0.86 (0.77-0.96)	[R]	[R]	[R]
Risk group (clinical)															
†Prior SARS-CoV-2	14,290 (10,625)	91.4	0.93 (0.92-0.95)	7,135 (4,690)	91.5	0.94 (0.91-0.97)	2,545 (1,400)	88.1	0.92 (0.87-0.97)	1,000 (670)	82.0	0.96 (0.88-1.04)	515 (400)	81.5	0.91 (0.82-1.00)
Immunosuppression	43,575 (37,735)	94.9	1.12 (1.11-1.14)	18,245 (14,895)	94.8	1.12 (1.10-1.15)	5,525 (3,980)	92.7	1.16 (1.11-1.20)	2,065 (1,540)	85.6	1.08 (1.02-1.15)	10,615 (8,995)	89.1	1.06 (1.01-1.12)
Moderate/severe obesity	71,070 (62,710)	92.6	0.97 (0.97-0.98)	27,390 (23,215)	92.9	0.97 (0.96-0.98)	8,000 (6,145)	90.7	0.97 (0.95-1.00)	1,325 (1,005)	87.5	1.09 (1.01-1.16)	1,160 (995)	89.0	1.07 (1.00-1.14)
Diabetes	152,745 (130,485)	92.8	0.95 (0.95-0.96)	81,390 (66,145)	92.9	0.96 (0.96-0.97)	27,680 (20,000)	91.0	0.98 (0.96-1.00)	4,040 (2,860)	87.5	1.03 (0.98-1.09)	4,040 (3,390)	89.9	1.07 (1.02-1.11)
CRD (inc. asthma)	136,395 (116,745)	93.6	1.01 (1.00-1.01)	54,735 (44,070)	93.9	1.02 (1.01-1.03)	14,675 (10,480)	91.7	1.01 (0.98-1.03)	2,035 (1,440)	86.9	1.03 (0.98-1.10)	2,255 (1,880)	88.0	0.96 (0.91-1.01)
Chronic heart disease	255,835 (219,880)	94.7	0.98 (0.98-0.99)	125,250 (100,865)	94.4	0.98 (0.97-0.99)	35,895 (25,480)	92.8	1.00 (0.98-1.02)	4,740 (3,355)	87.7	0.98 (0.94-1.03)	3,860 (3,195)	90.1	1.01 (0.96-1.05)
Chronic liver disease	20,250 (17,365)	92.1	1.01 (1.00-1.03)	7,650 (6,190)	92.3	1.01 (0.98-1.04)	2,245 (1,630)	90.3	1.01 (0.97-1.07)	550 (380)	80.5	1.00 (0.90-1.11)	585 (490)	88.8	1.07 (0.98-1.17)
Asplenia	5,485 (4,835)	94.7	1.10 (1.07-1.13)	2,035 (1,695)	93.5	1.10 (1.05-1.15)	575 (400)	87.4	0.97 (0.88-1.07)	140 (100)	83.3	1.09 (0.89-1.32)	[R]	[R]	[R]
Cancer (non-haematologic)	103,955 (89,290)	95.6	1.07 (1.07-1.08)	45,090 (36,250)	95.5	1.06 (1.05-1.08)	12,800 (9,115)	94.1	1.09 (1.06-1.11)	1,305 (965)	91.4	1.12 (1.05-1.21)	960 (820)	92.0	1.14 (1.06-1.22)
Haematologic cancer	11,885 (10,075)	95.6	1.03 (1.01-1.06)	5,705 (4,560)	95.5	1.05 (1.01-1.09)	1,845 (1,265)	92.7	0.99 (0.93-1.06)	[R]	[R]	[R]	240 (205)	89.6	1.11 (0.97-1.28)
Organ transplant (non-kidney)	1,195 (1,055)	92.0	1.39 (1.30-1.47)	685 (575)	93.0	1.36 (1.25-1.48)	[R]	[R]	[R]	[R]	[R]	[R]	[N]	[N]	[N]
CND (inc. learning disability)	96,415 (78,640)	93.7	0.90 (0.89-0.91)	46,255 (34,965)	93.4	0.91 (0.90-0.92)	12,905 (8,540)	91.6	0.92 (0.90-0.95)	1,440 (995)	86.0	0.92 (0.86-0.98)	1,185 (985)	89.2	0.96 (0.90–1.03)
Severe mental illness	10,465 (8,255)	86.4	0.77 (0.75–0.78)	4,105 (3,205)	89.6	0.85 (0.82–0.88)	1,310 (925)	87.1	0.91 (0.85-0.97)	220 (145)	72.2	0.83 (0.70-0.98)	170 (135)	81.2	0.85 (0.72–1.01)
CEV (other)	3,480 (2,990)	92.1	1.03 (0.99–1.07)	1,465 (1,195)	92.1	1.09 (1.03–1.16)	810 (630)	87.3	1.09 (1.01–1.18)	[N]	[N]	[N]	[N]	[N]	[N]

Counts are rounded to the nearest 5. Cumulative coverage was determined based on Kaplan-Meier estimates, censoring on death, deregistration, or 11th May 2022. Hazard ratios and 95% confidence intervals were derived from partially adjusted models that included age, care home residence, health and social care worker status, housebound status, receipt of end-of-life care, setting (urban/rural), sex, ethnicity, IMD quintile, prior SARS-CoV-2 infection, immunosuppression, and haematologic cancer. Data are redacted [R] for any rows in which there were >0 and ≤10 event or non-event counts after rounding to the nearest 5, with non-event counts calculated among uncensored individuals. CEV, clinically extremely vulnerable; CKD, chronic kidney disease; CND, chronic neurological disease; IMD, index of multiple deprivation; [N], covariate absent in all individuals by definition; [R] redacted; RRT, renal replacement therapy.

## Supplementary Table 4. Baseline characteristics of secondary outcome analysis population (dose 4 uptake).

Characteristic	All N = 679,405	CKD3a N = 418,095	CKD3b N = 193,475	CKD4-5 N = 50,465	RRT (dialysis) N = 4,595	RRT (transplant) N = 12,770
Age	,	•		·	•	· · · · · · · · · · · · · · · · · · ·
16–64	20,015 (2.9%)	6,775 (1.6%)	1,845 (1.0%)	800 (1.6%)	1,300 (28.3%)	9,295 (72.8%)
65–69	8,210 (1.2%)	4,705 (1.1%)	1,395 (0.7%)	435 (0.9%)	245 (5.3%)	1,425 (11.2%)
70–74	13,795 (2.0%)	8,730 (2.1%)	2,815 (1.5%)	825 (1.6%)	245 (5.3%)	1,180 (9.2%)
75–79	172,530 (25.4%)	124,030 (29.7%)	38,245 (19.8%)	8,410 (16.7%)	1,220 (26.6%)	620 (4.9%)
80+	464,860 (68.4%)	273,855 (65.5%)	149,170 (77.1%)	40,000 (79.3%)	1,590 (34.6%)	250 (2.0%)
Sex						
Female	387,500 (57.0%)	241,015 (57.6%)	112,810 (58.3%)	27,035 (53.6%)	1,710 (37.2%)	4,925 (38.6%)
Male	291,905 (43.0%)	177,080 (42.4%)	80,665 (41.7%)	23,430 (46.4%)	2,885 (62.8%)	7,845 (61.4%)
Ethnicity						
White	645,830 (95.1%)	399,635 (95.6%)	184,715 (95.5%)	47,335 (93.8%)	3,755 (81.7%)	10,390 (81.4%)
Mixed	2,740 (0.4%)	1,620 (0.4%)	710 (0.4%)	215 (0.4%)	60 (1.3%)	140 (1.1%)
Asian or Asian British	18,695 (2.8%)	9,955 (2.4%)	4,920 (2.5%)	1,820 (3.6%)	490 (10.7%)	1,510 (11.8%)
Black or Black British	8,275 (1.2%)	4,630 (1.1%)	2,155 (1.1%)	780 (1.5%)	235 (5.1%)	470 (3.7%)
Other ethnic groups	3,865 (0.6%)	2,255 (0.5%)	980 (0.5%)	315 (0.6%)	55 (1.2%)	260 (2.0%)
Index of multiple deprivation quintile	, , , , , , , , , , , , , , , , , , , ,	, , , , ,	• • •	, , ,	, ,	, ,
1 most deprived	103,695 (15.3%)	60,420 (14.5%)	30,950 (16.0%)	8,705 (17.2%)	1,015 (22.1%)	2,600 (20.4%)
2	124,970 (18.4%)	74,870 (17.9%)	36,495 (18.9%)	9,935 (19.7%)	1,005 (21.9%)	2,665 (20.9%)
3	155,525 (22.9%)	95,730 (22.9%)	44,525 (23.0%)	11,530 (22.8%)	980 (21.3%)	2,760 (21.6%)
4	152,900 (22.5%)	95,975 (23.0%)	42,745 (22.1%)	10,810 (21.4%)	845 (18.4%)	2,520 (19.7%)
5 least deprived	142,315 (20.9%)	91,100 (21.8%)	38,755 (20.0%)	9,485 (18.8%)	745 (16.2%)	2,225 (17.4%)
Setting	, , , , , , ,					
Urban city or town	362,390 (53.3%)	222,365 (53.2%)	103,970 (53.7%)	27,115 (53.7%)	2,320 (50.5%)	6,615 (51.8%)
Urban conurbation	138,875 (20.4%)	83,815 (20.0%)	39,355 (20.3%)	10,895 (21.6%)	1,320 (28.7%)	3,495 (27.4%)
Rural	178,145 (26.2%)	111,915 (26.8%)	50,150 (25.9%)	12,460 (24.7%)	960 (20.9%)	2,660 (20.8%)
Primary care coding of kidney disease	, , , ,	, , , , ,	, , , ,	, , ,	. , ,	, , , ,
CKD3–5 diagnostic code	424,480 (62.5%)	214,160 (51.2%)	151,790 (78.5%)	44,890 (89.0%)	3,985 (86.7%)	9,655 (75.6%)
Dialysis code	12,025 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3,720 (81.0%)	8,305 (65.0%)
Kidney transplant code	13,435 (2.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1,070 (23.3%)	12,360 (96.8%)
Risk group (occupation/access)	, , , ,	( , ,	( , ,		, , , ,	, , , ,
Care home resident	43,385 (6.4%)	23,700 (5.7%)	14,845 (7.7%)	4,605 (9.1%)	165 (3.6%)	65 (0.5%)
Health/social care worker	1,095 (0.2%)	565 (0.1%)	120 (0.1%)	35 (0.1%)	20 (0.4%)	355 (2.8%)
Housebound	49,420 (7.3%)	24,345 (5.8%)	17,740 (9.2%)	6,345 (12.6%)	375 (8.2%)	615 (4.8%)
End of life care	35,765 (5.3%)	17,935 (4.3%)	12,290 (6.4%)	4,995 (9.9%)	365 (7.9%)	180 (1.4%)
Risk group (clinical)	, (,-,	/ ( -/-/	, (- ,-,	, ( , - ,	(	( ,-,
Prior SARS-CoV-2 *	19,170 (2.8%)	10,080 (2.4%)	6,040 (3.1%)	2,065 (4.1%)	475 (10.3%)	515 (4.0%)
Immunosuppression	80,025 (11.8%)	43,575 (10.4%)	18,245 (9.4%)	5,525 (10.9%)	2,065 (44.9%)	10,615 (83.1%)
Moderate/severe obesity	55,040 (8.1%)	31,670 (7.6%)	16,970 (8.8%)	4,880 (9.7%)	360 (7.8%)	1,160 (9.1%)
Diabetes	190,140 (28.0%)	100,110 (23.9%)	62,990 (32.6%)	21,315 (42.2%)	1,685 (36.7%)	4,040 (31.6%)
Chronic respiratory disease (inc. asthma)	151,400 (22.3%)	91,725 (21.9%)	44,605 (23.1%)	11,810 (23.4%)	1,005 (21.9%)	2,255 (17.7%)
Chronic heart disease	340,605 (50.1%)	195,385 (46.7%)	107,965 (55.8%)	30,860 (61.2%)	2,535 (55.2%)	3,860 (30.2%)

Chronic liver disease	18,715 (2.8%)	11,090 (2.7%)	5,290 (2.7%)	1,505 (3.0%)	240 (5.2%)	585 (4.6%)
Asplenia	5,930 (0.9%)	3,650 (0.9%)	1,575 (0.8%)	455 (0.9%)	80 (1.7%)	170 (1.3%)
Cancer (non-haematologic)	128,475 (18.9%)	77,375 (18.5%)	38,315 (19.8%)	11,020 (21.8%)	805 (17.5%)	960 (7.5%)
Haematologic cancer	19,990 (2.9%)	11,885 (2.8%)	5,705 (2.9%)	1,845 (3.7%)	310 (6.7%)	240 (1.9%)
Organ transplant (non-kidney) †	2,170 (0.3%)	1,195 (0.3%)	685 (0.4%)	215 (0.4%)	75 (1.6%)	[N]
CND (inc. learning disability)	131,900 (19.4%)	77,535 (18.5%)	41,125 (21.3%)	11,295 (22.4%)	765 (16.6%)	1,185 (9.3%)
Severe mental illness	9,190 (1.4%)	5,405 (1.3%)	2,700 (1.4%)	835 (1.7%)	80 (1.7%)	170 (1.3%)
Clinically extremely vulnerable (other) §	3,990 (0.6%)	2,370 (0.6%)	1,170 (0.6%)	450 (0.9%)	[N]	[N]
Region						_
London	20,255 (3.0%)	11,740 (2.8%)	5,490 (2.8%)	1,800 (3.6%)	315 (6.9%)	910 (7.1%)
East of England	152,635 (22.5%)	94,895 (22.7%)	42,880 (22.2%)	10,840 (21.5%)	1,055 (23.0%)	2,970 (23.3%)
East Midlands	125,850 (18.5%)	77,615 (18.6%)	35,975 (18.6%)	9,215 (18.3%)	790 (17.2%)	2,250 (17.6%)
North East	31,955 (4.7%)	19,750 (4.7%)	9,150 (4.7%)	2,215 (4.4%)	240 (5.2%)	595 (4.7%)
North West	62,430 (9.2%)	38,315 (9.2%)	17,940 (9.3%)	4,700 (9.3%)	305 (6.6%)	1,165 (9.1%)
South East	42,580 (6.3%)	26,645 (6.4%)	11,810 (6.1%)	3,100 (6.1%)	290 (6.3%)	735 (5.8%)
South West	122,945 (18.1%)	76,210 (18.2%)	35,105 (18.1%)	9,145 (18.1%)	695 (15.1%)	1,790 (14.0%)
West Midlands	24,805 (3.7%)	14,830 (3.5%)	7,255 (3.7%)	1,975 (3.9%)	275 (6.0%)	465 (3.6%)
Yorkshire and the Humber	95,950 (14.1%)	58,095 (13.9%)	27,870 (14.4%)	7,480 (14.8%)	620 (13.5%)	1,885 (14.8%)

Individuals were included in the analysis if they were ≥75 years of age at baseline, care home residents, transplant recipients, or had a history of haematologic malignancy or immunosuppression. Data are n (%) after rounding to the nearest 5. Primary care codes and risk groups are coded by separate binary variables; percentages under these table subheadings therefore do not sum to 100. Among people with CKD4–5, 46,830 had stage 4 CKD (eGFR 15–29 ml/min/1.73 m²) and 3,635 had stage 5 CKD (eGFR <15ml/min/1.73 m²). CKD, chronic kidney disease; CND, chronic neurological disease; [N], covariate absent in all individuals by definition; RRT, renal replacement therapy. \*Based on prior evidence of a positive SARS-CoV-2 test, COVID-19-related primary care code, or COVID-19-related hospitalisation as of 1st December 2020; † Excludes individuals with kidney transplants based on primary care coding or UK Renal Registry status; § Classified as clinically extremely vulnerable in the absence of any of the comorbidities listed above (including RRT).

Supplementary Table 5. Cox proportional hazards models for factors associated with completion of a 4-dose vaccination series in people with kidney disease.

		Cov.	HR (95% CI), minimally	HR (95% CI), partially	HR (95% CI),
Variable	N (n events)	(%)	adjusted	adjusted	fully adjusted
*†Age		., .	,	· · · · · · · · · · · · · · · · · · ·	
16–64 (ref)	20,015 (8,005)	42.5	1.00	1.00	1.00
65–69	8,210 (3,340)	44.9	1.08 (1.04-1.12)	0.99 (0.95-1.03)	1.52 (1.45-1.58)
70–74	13,795 (6,090)	50.0	1.22 (1.18-1.26)	1.06 (1.03-1.10)	1.80 (1.73-1.87)
75–79	172,530 (99,315)	62.8	1.38 (1.35-1.41)	1.51 (1.47-1.54)	2.76 (2.67-2.85)
80+	464,860 (232,695)	61.9	1.41 (1.38-1.45)	1.59 (1.55-1.64)	2.95 (2.86-3.05)
†Sex					
Female (ref)	387,500 (192,935)	58.6	1.00	1.00	1.00
Male	291,905 (156,510)	64.4	1.19 (1.18-1.19)	1.17 (1.16-1.17)	1.16 (1.16-1.17)
†Ethnicity	( (				
White (ref)	645,830 (340,050)	62.5	1.00	1.00	1.00
Mixed	2,740 (875)	36.9	0.51 (0.47-0.54)	0.53 (0.50-0.57)	0.54 (0.50-0.57)
Asian or Asian British	18,695 (5,205)	32.8	0.44 (0.43-0.45)	0.48 (0.46-0.49)	0.47 (0.45-0.48)
Black or Black British	8,275 (1,805)	25.1	0.32 (0.31-0.34)	0.35 (0.33-0.37)	0.36 (0.34-0.37)
Other ethnic groups	3,865 (1,510)	46.5	0.69 (0.66-0.73)	0.71 (0.68-0.75)	0.69 (0.66-0.73)
†IMD	102 (05 (41 (90)	48.9	1.00	1.00	1.00
1 most deprived (ref) 2	103,695 (41,680) 124,970 (58,805)	56.5	1.23 (1.22-1.25)	1.00 1.19 (1.18-1.21)	1.19 (1.17-1.20)
3	155,525 (81,110)	61.8	1.40 (1.38-1.41)	1.32 (1.30-1.34)	1.31 (1.29-1.33)
4	152,900 (84,305)	64.8	1.51 (1.49-1.53)	1.42 (1.40-1.44)	1.40 (1.39-1.42)
5 least deprived	142,315 (83,545)	68.6	1.65 (1.63-1.67)	1.54 (1.53-1.56)	1.52 (1.50-1.54)
†Setting	112,010 (00,010)	00.0	1.05 (1.05 1.07)	1.01 (1.00 1.00)	1.32 (1.30 1.31)
Urban city or town (ref)	362,390 (186,715)	61.2	1.00	1.00	1.00
Urban conurbation	138,875 (64,560)	55.9	0.96 (0.95-0.97)	1.02 (1.01-1.03)	1.01 (1.00-1.03)
Rural town or village	178,145 (98,170)	64.7	1.08 (1.07-1.09)	1.00 (0.99-1.01)	1.00 (0.99-1.01)
Kidney disease subgroup	, , , , ,		, , ,		
CKĎ3a (ref)	418,095 (228,710)	62.5	1.00	1.00	1.00
CKD3b	193,475 (92,595)	59.3	0.91 (0.90-0.91)	0.92 (0.92-0.93)	0.92 (0.91-0.93)
CKD4–5	50,465 (19,400)	55.2	0.83 (0.82-0.84)	0.86 (0.85-0.87)	0.86 (0.85-0.87)
RRT (dialysis)	4,595 (1,715)	50.0	1.10 (1.05-1.15)	1.19 (1.13-1.24)	1.18 (1.12-1.23)
RRT (transplant)	12,770 (7,025)	58.9	2.71 (2.62-2.80)	2.96 (2.86-3.06)	3.08 (2.98-3.18)
Primary care coding of kidney disease					
CKD diagnostic code	424,480 (217,290)	61.2	1.00 (1.00-1.01)	1.02 (1.01-1.02)	1.04 (1.04-1.05)
Risk group (occupation/access)			0 (= (0 (= 0 (0)	()	(
*†Care home resident	43,385 (11,695)	49.5	0.67 (0.65-0.68)	0.73 (0.72-0.74)	0.79 (0.77-0.80)
*†Health/social care worker	1,095 (645)	59.6	1.46 (1.35-1.58)	1.50 (1.39-1.63)	1.46 (1.35-1.58)
†Housebound	49,420 (14,125)	43.3	0.57 (0.56-0.58)	0.60 (0.59-0.61)	0.61 (0.60-0.62)
†End of life care	35,765 (9,855)	51.4	0.83 (0.82-0.85)	0.88 (0.86-0.89)	0.88 (0.86-0.90)
Risk group (clinical)	10 170 (6 205)	E1 E	0.96 (0.94.0.90)	0.02 (0.00 0.04)	0.02 (0.00 0.05)
†Prior SARS-CoV-2	19,170 (6,395) 80,025 (38,925)	51.5 56.7	0.86 (0.84-0.89) 1.32 (1.30-1.33)	0.92 (0.90-0.94) 1.26 (1.24-1.28)	0.93 (0.90-0.95) 1.21 (1.20-1.23)
†Immunosuppression Moderate/severe obesity	55,040 (26,605)	55.1	0.84 (0.83-0.85)	0.89 (0.88-0.90)	0.92 (0.91-0.93)
Diabetes	190,140 (89,055)	57.2	0.87 (0.87-0.88)	0.92 (0.91-0.93)	0.93 (0.92-0.94)
CRD (inc. asthma)	151,400 (73,560)	59.6	0.97 (0.96-0.98)	1.00 (0.99-1.01)	1.01 (1.00-1.02)
Chronic heart disease	340,605 (167,470)	60.9	0.97 (0.97-0.98)	0.96 (0.95-0.97)	0.97 (0.97-0.98)
Chronic liver disease	18,715 (9,190)	58.3	1.01 (0.99-1.03)	1.03 (1.01-1.05)	1.03 (1.01-1.05)
Asplenia	5,930 (3,175)	63.2	1.12 (1.08-1.16)	1.09 (1.05-1.12)	1.08 (1.05-1.12)
Cancer (non-haematologic)	128,475 (66,290)	64.3	1.10 (1.09-1.11)	1.07 (1.06-1.08)	1.07 (1.06-1.08)
†Haematologic cancer	19,990 (10,400)	64.4	1.47 (1.44-1.50)	1.23 (1.20-1.26)	1.33 (1.30-1.36)
Organ transplant (non-kidney)	2,170 (1,210)	62.3	1.81 (1.71-1.92)	1.82 (1.72-1.93)	2.41 (2.28-2.56)
CND (inc. learning disability)	131,900 (55,625)	56.2	0.86 (0.85-0.87)	0.87 (0.86-0.88)	0.88 (0.87-0.89)
Severe mental illness	9,190 (3,195)	44.0	0.67 (0.65-0.69)	0.72 (0.69-0.74)	0.74 (0.71-0.76)
CEV (other)	3,990 (2,045)	61.2	1.04 (1.00-1.09)	1.10 (1.05-1.15)	1.05 (1.01-1.10)

Curvaluative coverage was determined based on Kaplan-Meier estimates, censoring on death, deregistration, or 11<sup>th</sup> May 2022. \* variable included in all minimally adjusted models; † variable included in all partially adjusted models. CI, confidence interval; CKD, chronic kidney disease; HR, hazard ratio; IMD, index of multiple deprivation; OR, odds ratio; RRT, renal replacement therapy.

Supplementary Table 6. Cox proportional hazards models for factors associated with completion of a 3-dose vaccination series in kidney disease subgroups.

		CKD3a	CKD3a CKD3b			CKD4-5			RRT (dialysis)			RRT (transplant)			
Variable	N (n events)	Cov. (%)	HR (95% CI)	N (n events)	Cov. (%)	HR (95% CI)	N (n events)	Cov. (%)	HR (95% CI)	N (n events)	Cov. (%)	HR (95% CI)	N (n events)	Cov. (%)	HR (95% CI)
Age															
16-64 (ref)	6,775 (2,000)	31.0	1.00	1,845 (585)	34.4	1.00	800 (255)	35.4	1.00	1,300 (440)	37.3	1.00	9,295 (4,730)	53.3	1.00
65-69	4,705 (1,630)	37.2	1.21 (1.13-1.29)	1,395 (515)	41.3	1.21 (1.08-1.37)	435 (165)	43.7	1.36 (1.11-1.65)	245 (85)	40.8	1.22 (0.97-1.54)	1,425 (945)	72.1	1.60 (1.49-1.72)
70-74	8,730 (3,790)	47.9	1.61 (1.52-1.70)	2,815 (1,105)	46.0	1.27 (1.15-1.41)	825 (305)	48.1	1.37 (1.16-1.62)	245 (90)	48.1	1.35 (1.07-1.70)	1,180 (800)	75.9	1.67 (1.55-1.81)
75–79	124,030 (74,145)	63.9	2.58 (2.46-2.71)	38,245 (20,495)	59.9	1.97 (1.81-2.15)	8,410 (3,765)	56.3	1.76 (1.54-2.02)	1,220 (495)	55.6	1.45 (1.19-1.75)	620 (410)	76.2	1.67 (1.51-1.85)
80+	273,855 (147,145)	63.7	2.79 (2.66-2.92)	149,170 (69,900)	59.9	2.12 (1.95-2.30)	40,000 (14,910)	55.7	1.82 (1.59-2.08)	1,590 (605)	58.1	1.62 (1.33-1.96)	250 (140)	73.5	1.68 (1.42-1.99)
Sex															
Female (ref)	241,015 (127,790)	60.2	1.00	112,810 (51,900)	56.4	1.00	27,035 (9,830)	51.4	1.00	1,710 (585)	44.9	1.00	4,925 (2,825)	60.8	1.00
Male	177,080 (100,920)	65.8	1.15 (1.14-1.16)	80,665 (40,695)	63.3	1.19 (1.18-1.21)	23,430 (9,565)	59.8	1.24 (1.20-1.27)	2,885 (1,130)	52.8	1.19 (1.07-1.31)	7,845 (4,200)	57.7	0.92 (0.87-0.96)
Ethnicity															
White (ref)	399,635 (223,240)	63.9	1.00	184,715 (90,355)	60.6	1.00	47,335 (18,735)	57.0	1.00	3,755 (1,480)	54.0	1.00	10,390 (6,240)	64.3	1.00
Mixed	1,620 (550)	38.1	0.54 (0.50-0.59)	710 (210)	35.5	0.51 (0.45-0.58)	215 (55)	33.3	0.59 (0.45-0.77)	60 (15)	20.0	0.59 (0.35-0.97)	140 (45)	30.8	0.49 (0.36-0.65)
Asian or Asian British	9,955 (2,965)	33.8	0.46 (0.45-0.48)	4,920 (1,220)	30.5	0.45 (0.43-0.48)	1,820 (360)	28.1	0.46 (0.41-0.51)	490 (140)	35.6	0.59 (0.49-0.71)	1,510 (515)	36.1	0.51 (0.47-0.56)
Black or Black British	4,630 (1,020)	24.4	0.34 (0.32-0.36)	2,155 (455)	24.9	0.37 (0.33-0.40)	780 (150)	23.1	0.39 (0.33-0.46)	235 (60)	32.6	0.53 (0.40-0.69)	470 (120)	27.3	0.38 (0.32-0.46)
Other ethnic groups	2,255 (935)	47.4	0.70 (0.66-0.75)	980 (355)	44.2	0.70 (0.63-0.78)	315 (100)	42.8	0.75 (0.61-0.91)	55 (15)	20.0	0.59 (0.35-0.98)	260 (105)	41.7	0.63 (0.51-0.76)
IMD															
1 most deprived (ref)	60,420 (26,045)	50.4	1.00	30,950 (11,780)	48.2	1.00	8,705 (2,590)	43.7	1.00	1,015 (285)	36.5	1.00	2,600 (985)	40.3	1.00
2	74,870 (37,585)	58.0	1.19 (1.17-1.21)	36,495 (16,045)	55.0	1.17 (1.14-1.20)	9,935 (3,525)	51.5	1.19 (1.13-1.25)	1,005 (355)	47.4	1.40 (1.19-1.64)	2,665 (1,290)	51.5	1.37 (1.26-1.49)
3	95,730 (52,840)	63.0	1.31 (1.29-1.33)	44,525 (21,715)	60.2	1.30 (1.27-1.33)	11,530 (4,530)	56.3	1.30 (1.23-1.37)	980 (395)	53.1	1.54 (1.31-1.81)	2,760 (1,625)	63.0	1.69 (1.55-1.83)
4	95,975 (55,950)	66.1	1.41 (1.39-1.43)	42,745 (21,840)	62.8	1.39 (1.36-1.42)	10,810 (4,560)	59.3	1.40 (1.33-1.47)	845 (355)	55.4	1.61 (1.37-1.91)	2,520 (1,605)	67.9	1.86 (1.71-2.02)
5 least deprived	91,100 (56,295)	69.7	1.53 (1.51-1.55)	38,755 (21,215)	66.6	1.51 (1.48-1.55)	9,485 (4,195)	62.8	1.49 (1.42-1.57)	745 (320)	57.7	1.73 (1.46-2.05)	2,225 (1,525)	72.7	2.05 (1.88-2.23)
Setting			· ·			· ·									
Urban city or town (ref)	222,365 (121,865)	62.7	1.00	103,970 (50,030)	59.6	1.00	27,115 (10,385)	55.1	1.00	2,320 (805)	46.6	1.00	6,615 (3,630)	58.8	1.00
Urban conurbation	83,815 (41,785)	57.7	1.02 (1.01-1.04)	39,355 (16,900)	53.9	1.01 (0.99-1.03)	10,895 (3,770)	50.1	1.04 (0.99-1.09)	1,320 (480)	47.4	1.08 (0.92-1.26)	3,495 (1,625)	49.5	1.05 (0.97-1.14)
Rural town or village	111,915 (65,065)	65.8	1.00 (0.99-1.01)	50,150 (25,665)	62.7	0.99 (0.98-1.01)	12,460 (5,245)	60.0	1.03 (0.99-1.06)	960 (430)	59.9	1.19 (1.06-1.35)	2,660 (1,770)	71.0	1.17 (1.10-1.23)
Primary care coding of kidney disease									· · · · · · · · · · · · · · · · · · ·	` '		· · · · · · · · · · · · · · · · · · ·			
CKD diagnostic code	214,160 (118,570)	63.2	1.03 (1.02-1.03)	151,790 (74,260)	59.9	1.07 (1.05-1.08)	44,890 (17,535)	55.6	1.06 (1.01-1.12)	3,985 (1,485)	50.7	0.98 (0.85-1.14)	9,655 (5,435)	60.6	1.13 (1.07-1.19)
Risk group (occupation/access)															
Care home resident	23,700 (6,855)	49.5	0.72 (0.70-0.74)	14,845 (3,800)	49.4	0.76 (0.74-0.79)	4,605 (995)	49.9	0.86 (0.80-0.92)	165 (30)	22.2	0.64 (0.44-0.94)	65 (20)	33.3	0.46 (0.30-0.72)
Health/social care worker	565 (325)	58.1	1.53 (1.37-1.70)	120 (70)	50.0	1.36 (1.08-1.73)	[R]	[R]	[R]	[R]	[R]	[R]	355 (225)	61.1	1.31 (1.15-1.50)
Housebound	24,345 (7,520)	44.2	0.59 (0.58-0.60)	17,740 (4,835)	42.1	0.59 (0.58-0.61)	6,345 (1,320)	38.8	0.60 (0.57-0.64)	375 (100)	44.9	0.88 (0.72-1.08)	615 (345)	61.5	0.95 (0.85-1.06)
End of life care	17,935 (5,395)	52.4	0.87 (0.84-0.89)	12,290 (3,240)	50.5	0.89 (0.86-0.92)	4,995 (1,035)	48.5	0.92 (0.86-0.98)	365 (90)	43.5	0.77 (0.63-0.96)	180 (90)	68.3	1.26 (1.02-1.56)
Risk group (clinical)															
Prior SARS-CoV-2	10,080 (3,705)	53.2	0.92 (0.89-0.95)	6,040 (1,840)	50.4	0.92 (0.87-0.96)	2,065 (485)	47.0	0.91 (0.83-1.00)	475 (140)	41.7	0.85 (0.71-1.02)	515 (230)	46.7	0.88 (0.77-1.00)
Immunosuppression	43,575 (21,400)	55.8	1.22 (1.19-1.24)	18,245 (8,595)	58.1	1.26 (1.22-1.29)	5,525 (2,200)	55.9	1.34 (1.26-1.42)	2,065 (750)	44.2	1.05 (0.88-1.25)	10,615 (5,975)	60.3	1.17 (1.10-1.26)
Moderate/severe obesity	31,670 (16,170)	56.1	0.90 (0.89-0.92)	16,970 (7,815)	54.1	0.91 (0.89-0.93)	4,880 (1,865)	50.4	0.92 (0.87-0.96)	360 (130)	45.9	0.99 (0.83-1.19)	1,160 (630)	56.7	1.03 (0.95-1.12)
Diabetes	100,110 (50,045)	58.2	0.91 (0.90-0.92)	62,990 (28,520)	56.6	0.94 (0.93-0.96)	21,315 (7,790)	53.1	0.95 (0.92-0.98)	1,685 (555)	48.2	0.96 (0.86-1.06)	4,040 (2,145)	58.4	1.03 (0.98-1.09)
CRD (inc. asthma)	91,725 (47,415)	60.9	1.00 (0.99-1.01)	44,605 (20,325)	58.2	1.01 (0.99-1.02)	11,810 (4,285)	54.3	1.01 (0.98-1.05)	1,005 (355)	50.1	1.08 (0.96-1.21)	2,255 (1,175)	56.1	0.93 (0.87-0.99)
Chronic heart disease	195,385 (103,225)	62.5	0.96 (0.95-0.97)	107,965 (49,800)	59.2	0.97 (0.96-0.99)	30,860 (11,355)	55.5	0.98 (0.95-1.01)	2,535 (910)	51.4	0.98 (0.89-1.08)	3,860 (2,185)	63.3	1.05 (0.99-1.10)
Chronic liver disease	11,090 (5,770)	59.4	1.05 (1.02-1.08)	5,290 (2,410)	56.3	1.02 (0.98-1.06)	1,505 (585)	55.0	1.06 (0.98-1.16)	240 (85)	44.4	1.18 (0.94-1.47)	585 (340)	60.9	1.22 (1.09-1.36)
Asplenia	3,650 (2,075)	64.5	1.09 (1.04-1.14)	1,575 (795)	61.1	1.10 (1.02-1.18)	455 (180)	55.5	1.08 (0.93-1.25)	80 (35)	50.0	1.51 (1.07-2.14)	170 (90)	56.2	0.98 (0.80-1.20)
Cancer (non-haematologic)	77,375 (42,645)	65.7	1.07 (1.06-1.09)	38,315 (18,430)	62.4	1.07 (1.05-1.09)	11,020 (4,295)	59.0	1.08 (1.05-1.12)	805 (320)	54.7	1.05 (0.93-1.19)	960 (600)	70.7	1.16 (1.07-1.26)
Haematologic cancer	11,885 (6,460)	64.3	1.33 (1.29-1.36)	5,705 (2,895)	64.8	1.33 (1.27-1.39)	1,845 (765)	61.5	1.32 (1.20-1.44)	310 (135)	58.6	1.70 (1.40-2.06)	240 (145)	63.6	1.06 (0.90-1.25)
Organ transplant (non-kidney)	1,195 (700)	62.4	2.57 (2.38-2.77)	685 (365)	60.8	2.26 (2.03-2.52)	215 (110)	57.2	1.97 (1.62-2.40)	75 (35)	42.9	1.72 (1.23-2.41)	[N]	[N]	[N]
CND (inc. learning disability)	77,535 (35,190)	57.6	0.87 (0.86–0.88)	41,125 (16,030)	54.3	0.87 (0.85–0.88)	11,295 (3,520)	51.6	0.90 (0.87-0.94)	765 (235)	44.6	0.87 (0.76–1.01)	1,185 (645)	60.1	1.01 (0.93-1.09)
Severe mental illness	5,405 (1,945)	43.8	0.70 (0.67-0.74)	2,700 (895)	43.6	0.74 (0.70-0.79)	835 (250)	44.9	0.85 (0.75-0.96)	80 (20)	28.6	0.71 (0.46–1.09)	170 (85)	50.0	0.99 (0.79–1.22)
CEV (other)	2,370 (1,280)	61.8	1.09 (1.03–1.15)	1.170 (575)	60,5	1.15 (1.06–1.25)	450 (190)	55,3	1.10 (0.96–1.27)	[N]	[N]	[N]	[N]	[N]	[N]
T 1: 1 1 1 1 1		• • • • • • • • • • • • • • • • • • • •				1. 1			(/)		1 1	1	. 1 .	17.7	

Individuals were included in the analysis if they were  $\ge 75$  years of age at baseline, care home residents, transplant recipients, or had a history of haematologic malignancy or immunosuppression. Counts are rounded to the nearest 5. Cumulative coverage was determined based on Kaplan-Meier estimates, censoring on death, deregistration, or  $11^{th}$  May 2022. Hazard ratios and 95% confidence intervals were derived from partially adjusted models that included age, care home residence, health and social care worker status, housebound status, receipt of end-of-life care, setting (urban/rural), sex, ethnicity, IMD quintile, prior SARS-CoV-2 infection, immunosuppression, and haematologic cancer. Data are redacted [R] for any rows in which there were >0 and  $\le 10$  event or non-event counts after rounding to the nearest 5, with non-event counts calculated among uncensored individuals. CEV, clinically extremely vulnerable; CKD, chronic kidney disease; CND, chronic neurological disease; IMD, index of multiple deprivation; [N], covariate absent in all individuals by definition; [R] redacted; RRT, renal replacement therapy.